Electronic feta l heart rate (FHR) monitoring was introduced in the late 1960s with the hope of preventing intrapartum fetal brain injury and cerebral palsy (CP). However, it is now clear that this hope was unrealistic for at least 2 reasons. First, the false-positive rate of intrapartum FHR monitoring for predicting CP exceeds 99%. Except in the most extreme cases, intrapartum FHR monitoring has never been capable of reliably predicting CP.
Electronic fetal heart rate (FHR) monitoring was introduced in the late 1960s with the hope of preventing intrapartum fetal brain injury and cerebral palsy (CP).1 However, it is now clear that this hope was unrealistic for at least 2 reasons. First, the false-positive rate of intrapartum FHR monitoring for predicting CP exceeds 99%.2 Except in the most extreme cases, intrapartum FHR monitoring has never been capable of reliably predicting CP. Second, most cases of CP originate outside the intrapartum period and therefore cannot be prevented by any form of intrapartum monitoring or intervention.3
A growing body of evidence indicates that standardization of intrapartum management can reduce adverse outcomes and professional liability claims.4,5 However, for many years, standardization of FHR monitoring was impeded by lack of consensus. Without evidence-based standardization, clinicians were left without clear guidance and often found themselves facing unfounded accusations of mismanagement.
Standardized definitions
Standardized interpretation
Scientific evidence and consensus in the literature can distill intrapartum FHR interpretation into 3 central concepts.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More